Positive effects of both PDE3 and PDE4 inhibitors in COVID-19 might be demonstrated by the ongoing clinical trial no. NCT04527471, where dual PDE3/PDE4 inhibitor ensifentrine (RPL554) has been administered inhalationally via pressurized metered dose inhaler (pMDI) twice daily. This evidence concerns the gene PDE4A and COVID-19.